<DOC>
	<DOCNO>NCT00105586</DOCNO>
	<brief_summary>This study determine efficacy escitalopram ( LexaproÂ® ) , anti-anxiety drug , generalize anxiety disorder ( GAD ) way genetics affect response treatment GAD elderly individual .</brief_summary>
	<brief_title>Drug Therapy Generalized Anxiety Disorder Among Elderly</brief_title>
	<detailed_description>GAD serious public health issue ; particularly among elderly , prevalence condition high , functional burden illness significant . GAD associate irregular level neurotransmitter , chemical carry message across nerve ending . Serotonin neurotransmitter help regulate mood emotion ; increase level serotonin show reduce anxiety . Standard treatment GAD typically involve selective serotonin reuptake inhibitor ( SSRIs ) , drug reduce serotonin re-entry nerve cell . Escitalopram SSRI well tolerate highly specific serotonin transporter ( SERT ) . The primary aim study examine efficacy escitalopram reduce anxiety symptom among elderly GAD patient . Additional aim include examine efficacy escitalopram improve function , quality life , neuropsychological functioning , examine whether genetic variation SERT gene influence participant ' response treatment . Participants randomly assign receive either escitalopram placebo 12 week ( also 12 week open label extension participant receive escitalopram ) . Participants weekly/biweekly study visit ; visit , participant complete self-report questionnaire functional ability anxiety symptom . Blood collection cognitive test various task also occur .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Diagnosis least moderately severe generalize anxiety disorder ( GAD ) Serious suicide risk psychiatric instability would affect study participation Dementia Substance abuse , alcoholism , within 6 month prior study entry Diagnosis schizophrenia , schizoaffective disorder , delusional disorder , bipolar disorder Unstable medical condition would preclude use escitalopram Use certain psychotropics safely taper discontinue least 2 week prior study Use neuroleptic absorb prolonged period time within 6 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>Elderly</keyword>
	<keyword>Aged</keyword>
	<keyword>Serotonin Reuptake Inhibitors</keyword>
	<keyword>SSRI</keyword>
	<keyword>SERT</keyword>
</DOC>